Spots Global Cancer Trial Database for Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Official Title: Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Study ID: NCT04730583
Conditions
Study Description
Brief Summary: This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States
Contact Details
Name: R. Rox Anderson, MD
Affiliation: Wellman Center for Photomedicine, Massachusetts General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
